A5002119977- Cancer Immunotherapy and Biomarkers
- Mathematical Biology Tumor Growth
- Immunotherapy and Immune Responses
- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Sarcoma Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Genetic factors in colorectal cancer
- Lymphoma Diagnosis and Treatment
- Cancer Treatment and Pharmacology
- Hepatocellular Carcinoma Treatment and Prognosis
- Colorectal and Anal Carcinomas
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Pituitary Gland Disorders and Treatments
- Monoclonal and Polyclonal Antibodies Research
- Occupational and environmental lung diseases
- Cancer, Hypoxia, and Metabolism
- Adrenal and Paraganglionic Tumors
- Radiation Dose and Imaging
- Transplantation: Methods and Outcomes
- Immune Cell Function and Interaction
- Endometrial and Cervical Cancer Treatments
- Radiation Therapy and Dosimetry
- Multiple Myeloma Research and Treatments
- Pancreatic and Hepatic Oncology Research
Inserm
2016-2025
Aix-Marseille Université
2016-2025
Pitié-Salpêtrière Hospital
2025
Sorbonne Université
2025
Hôpital Universitaire Dupuytren
2022
Centre de Recherche en Cancérologie de Marseille
2018-2020
Centre Hospitalier Universitaire de Limoges
2020
Centre National de la Recherche Scientifique
2018
Combining radiotherapy with immune checkpoint blockade may offer considerable therapeutic impact if the immunosuppressive nature of tumor microenvironment (TME) can be relieved. In this study, we used mathematical models, which illustrate potential synergism between inhibitors and radiotherapy. A discrete-time pharmacodynamic model combination PD1-PDL1 axis and/or CTLA4 pathway is described. This framework describes how a growing first elicits then inhibits an antitumor response. response...
// Fabrice Barlesi 1, 2 , Diane-Charlotte Imbs Pascale Tomasini 1 Laurent Greillier Melissa Galloux Albane Testot-Ferry Mélanie Garcia 3 Xavier Elharrar Annick Pelletier Nicolas André 2, 4 Céline Mascaux Bruno Lacarelle Raouf El Cheikh Raphaël Serre Joseph Ciccolini and Dominique Barbolosi Aix Marseille University, APHM, Early Phases Cancer Trials Center CLIP, Marseille, France SMARTc Unit, INSERM U911, Department of Pharmacology, Pediatric Hematology Oncology,...
Concomitant radiotherapy with immune checkpoint blockade could be synergistic. Out-of-field effects improve survival by slowing or blocking metastatic spreading. However, not much is known about the optimal size per fraction and inter-fraction time in that new context.The concept of Immunologically Effective Dose (IED) proposed: it models an intrinsic immunogenicity schedules, i.e. results from choice dosing regimen. The IED defined as single dose, given infinitely low dose rate, produces...
Radioiodine therapy (RAI) has traditionally been used as treatment for metastatic thyroid cancer, based on its ability to concentrate iodine. Propositions maximize tumor response with minimizing toxicity, must recognize the infinite possibilities of empirical tests. Therefore, an approach this study was build a mathematical model describing growth kinetics thyroglobulin (Tg) concentrations over time, following RAI cancer.Data from 50 patients papillary carcinoma treated within eight French...
Up to 50% of soft tissue sarcoma (STS) patients develop metastases in the course their disease. Cytotoxic therapy is a standard treatment this setting but yields average tumour response rates 25% at first line and ≤10% later lines. In oligometastatic stage, stereotactic body radiation (SBRT) allows reaching high control treated sites (≥80%) potentially equally effective surgery term overall survival. order shift balance towards antitumour immunity by multisite irradiation, could be combined...
Succinate dehydrogenase subunit B and D (SDHB SDHD) mutations represent the most frequent cause of hereditary pheochromocytoma paraganglioma (PPGL). Although truncation succinate complex is thought to be disease causing mechanism in both disorders, SDHB SDHD patients exihibit different phenotypes. These phenotypic differences are currently unexplained by molecular genetics. The aim this study compare dynamics these two conditions via a Markov chain model based on 4 clinically-defined steady...
<div>Abstract<p>Combining radiotherapy with immune checkpoint blockade may offer considerable therapeutic impact if the immunosuppressive nature of tumor microenvironment (TME) can be relieved. In this study, we used mathematical models, which illustrate potential synergism between inhibitors and radiotherapy. A discrete-time pharmacodynamic model combination PD1–PDL1 axis and/or CTLA4 pathway is described. This framework describes how a growing first elicits then inhibits an...
e23553 Background: Trabectedin (ET-743, Yondelis) is an antineoplastic agent indicated for the treatment of advanced soft tissue sarcomas (STS). Despite its efficacy, induces severe toxic side effects, especially neutropenia. In clinical settings, this leads to empirical dosing adjustments that disrupt efficacy-toxicity balance. Developing a quantitative tool allows better using patients-specific data would be great utility. Methods: Retrospective hematologic, demographic and disease status...
Abstract The rise of immunotherapy is a major breakthrough in oncology. Recently, the combination radiotherapy with blockade immune checkpoint inhibitors such as PD1-PDL1 axis or CTLA4 pathway has shown synergistic potential: addition to direct cell kill induced by irradiation, unleashes neoantigens that can further induce an anti-tumoral response. However, this response be inhibited immunosuppressive nature tumor micro-environment (TME). Hence, combined check-point promising solution and...
<p>The Supplementary Material section contains detailed mathematical information related to the model presented in article.</p>
<p>The Supplementary Material section contains detailed mathematical information related to the model presented in article.</p>
<div>Abstract<p>Combining radiotherapy with immune checkpoint blockade may offer considerable therapeutic impact if the immunosuppressive nature of tumor microenvironment (TME) can be relieved. In this study, we used mathematical models, which illustrate potential synergism between inhibitors and radiotherapy. A discrete-time pharmacodynamic model combination PD1–PDL1 axis and/or CTLA4 pathway is described. This framework describes how a growing first elicits then inhibits an...
Abstract Chemotherapy and immunotherapy have sometimes been considered two mutually exclusive approaches. On the one hand, chemotherapy has long as a modestly effective treatment (outside pediatric oncology), with short-lived effect caused by drug resistance, poor tolerance profile detrimental on immune system. other oncologist continues using chemotherapies for many reasons: if control of large tumor mass to be obtained urgently irrespective side effects system, failed or not validated...
Abstract Over the last decade, metronomic chemotherapy (MC) has emerged as an alternative way to administrate chemotherapy. MC can be defined regular administration of low/less-toxic doses without extended drug-free breaks. Because countless schedules are possible, testing them empirically looks like unachievable goal. Therefore, mathematical modeling effective tool determine appropriate strategies. A phase Ia/Ib study based on a model oral vinorelbine in metastatic NSCLC and malignant...
e20505 Background: A phase I/II trial (NCT02555007) of oral metronomic Vinorelbine derived from a mathematical model was performed in heavily pretreated metastatic Non-Small Cell Lung Cancer or Pleural Mesothelioma patients. Progression free survival, toxicity and PK/PD endpoints were the main objectives. Methods: Metronomic scheduling selected using simplified phenomenological to identify best continuous dosing vinorelbine with total dose 150 mg QW. Patients monitored on weekly basis,...